It is gratifying that ILUVIEN continues to show positive results both in stage 4 clinical studies and in European physician's practices in individuals who were considered insufficiently attentive to other treatments, said Dan Myers, president and chief executive officer, Alimera Sciences. These early email address details are in keeping with our belief that ILUVIEN would perform as well in clinical practice as was experienced in the FAME Research. We are very happy to work with the AIBILI team because they continue to follow the RESPOND sufferers, and we anticipate the 12-month outcomes. .. Alimera Sciences announces outcomes from ongoing study on ILUVIEN Alimera Sciences, Inc.Pending its evaluation, the FDA is urging health care professionals to consider prescribing an alternative solution pain medicine approved for children. Continue Reading >> 3. Clozapine In late September, the FDA transformed the dispensing requirements for the schizophrenia medication clozapine to handle ongoing safety concerns about severe neutropenia. The first change involves new prescribing info that clarifies how healthcare experts should manage clozapine treatment and monitor patients for neutropenia. Now, neutropenia will end up being monitored just by the total neutrophil count , than in conjunction with the white blood cell count rather.